Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics was founded in 2015 with the mission of developing highly effective aerosolized inhaler solutions for the inhaled treatment of respiratory diseases such as COPD, asthma, and cystic fibrosis. Since then, we have assembled a skilled team, partnered with leading experts in the field of aerosolized inhalation therapies, and begun our clinical development program.
At Aerovate Therapeutics, we are dedicated to developing inhaler solutions that improve the lives of patients suffering from respiratory diseases. Our mission is to create safe, effective, and convenient aerosolized treatments that can be used to help alleviate the symptoms of respiratory diseases and improve overall patient quality of life.
Our vision is to be the global leader in aerosolized inhaler therapies, providing innovative solutions to help improve the lives of patients and their families around the world. We strive to be a trusted and respected brand in the aerosolized inhaler therapies industry and to be a go-to partner for manufacturers, pharmaceutical companies, healthcare providers, and patients everywhere.
